Clinical Trial: Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07369596) titled 'Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations' on Dec. 22, 2025.

Brief Summary: Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity.

This study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.

Study Start Date: Jan. ...